Anti-CD166/ALCAM antibody

Cat.#: 105666

Size:

Special Price 193.4 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-CD166/ALCAM antibody
  • Documents
  • Description
    Rabbit monoclonal to CD166/ALCAM
  • Tested applications
    ELISA, WB
  • Species reactivity
    Rat CD166 / ALCAM
    Has cross-reactivity in ELISA with Human ALCAM
    No cross-reactivity in ELISA with Human BCAM
  • Alternative names
    AI853494 antibody; ALCAM antibody; BEN antibody; CD166 antibody; DM-GRASP antibody; MGC27910 antibody; MuSC antibody; SC1 antibody; MEMD antibody; CD166 antibody; BEN antibody; SC1 antibody; MuSC antibody; CD166 antibody; AI853494 antibody; DM-GRASP antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    This antibody was obtained from a rabbit immunized with purified, recombinant Rat CD166 / ALCAM (rh CD166 / ALCAM; O35112; Met1-Lys527).
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    WB: 1-10 μg/ml

    ELISA: 0.1-0.2 μg/mL

    This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Rat CD166 / ALCAM. The detection limit for Rat CD166 / ALCAM is 0.00975 ng/well.

  • Validations

    CD166 / ALCAM Antibody, Rabbit MAb

    CD166 / ALCAM Antibody, Rabbit MAb

  • Background
    Activated leukocyte cell adhesion molecule (ALCAM)/Cluster of differentiation (CD166) is a type I transmembrane cell adhesion molecule belonging to the Ig superfamily and a ligand for CD6 that is expressed on T lymphocytes. The extracellular domain of ALCAM contains five Ig-like domains (three Ig-like C2-type domains and two Ig-like V-type domains), of which the amino-terminal V1 domain is essential for ligand binding and ALCAM-mediated cell aggregation. ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. ALCAM/CD6 interaction plays a role in T cell development and T cell regulation, as well as in the binding of T- and B-cells to activated leukocytes. Recently, homophilic (ALCAM-ALCAM) adhesion was shown to play important roles in tight cell-to-cell interaction and regulation of stem cell differentiation. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. And CD166 is regarded as a potential novel breast cancer indicator and therapeutic target.
  • References
    • Swart GW. (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81(6): 313-21.
    • Fujiwara H, et al. (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab. 88(7): 3437-43.
    • Jezierska A, et al. (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit. 12(8): BR263-73.
    • Kahlert C, et al. (2009) Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 101(3): 457-64.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"